Résonance magnétique cardiaque (RMC) c’est une technique sans rayonnement, qui est considérée comme l’étalon-or pour l’évaluation de l’anatomie cardiaque, de la fonction et même de la composition des tissus. L’essai RESILIENCE utilisera la RMC comme principale méthodologie de mesure des résultats, et les patients inscrits à l’essai subiront 3 examens pendant toute la durée de l’étude.
Essai clinique multinational, prospectif, de preuve de concept de phase II, à double insu, contrôlé par simulation, randomisé (ECR) pour évaluer l’efficacité et l’innocuité du préconditionnement ischémique distal (RIC) chez les patients atteints de Lymphome recevant des anthracyclines. Les patients devant subir ≥5 cycles de chimiothérapie seront éligibles.
RESILIENCE has expanded the spectrum of patients who can enter its clinical trial. Thus, those people with breast cancer being treated with anthracyclines who meet the criteria assessed by their oncologists may be eligible to participate in the trial. The remote ischemic conditioning (RIC) to which these cancer patients will
We welcome Príncipe de Asturias University Hospital in Madrid, that has just joined the RESILIENCE project, together we will keep on working with the aim of helping people with cancer to live with a strong heart. The Príncipe de Asturias University Hospital is located in the city of Alcalá de
We are happy to share that our RESILIENCE project keeps on growing! Jacques Monod Hospital, part of the Le Havre Hospital Group and a reference hospital in the Seine Estuary Territory in France with a comprehensive range of care, joined RESILIENCE in November. At our meeting we talked about the
On November 7th we organized an open workshop and roundtable to celebrate the Science and Innovation Week on the Spanish National Center for Cardiovascular Research. Under the title “What is the relationship between cardiovascular disease and cancer? », thirty students from 15 to 16 years old attended the event along with
Infanta Leonor University Hospital joined the RESILIENCE project in September and with its participation in this clinical trial we continue to grow with the aim of providing a higher quality of life to patients who have overcome cancer, with the reduction of possible cardiac complications due to oncological treatment. The
In the framework of the Madrid Science and Innovation Week to be celebrated in Madrid on November 4-17th, our team RESILIENCE has planned an activity open to public of all ages upon registration. There will be a workshop and roundtable under the title “What is the relationship between cardiovascular disease
